53 completed, 10 recruiting, 9 unknown, 8 terminated. 35 Phase 2, 14 Phase 1, 10 Not applicable, 10 Phase 3, 2 Phase 4.
Follow Mastocytosis, Systemic: new trials by email Literature Review of Mastocytosis, Systemic trials Research Report on Mastocytosis, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Precision Medicine for Indolent Systemic Mastocytosis (PRISM) Systemic Mastocytosis | Not yet recruiting | Mayo Clinic | 25 | 2026-09-09 | 2026-08-18 | |
| An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) Indolent Systemic Mastocytosis | Recruiting | Blueprint Medicines Corporation | 150 | 2026-04-15 | 2026-09-04 | |
| A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany Avapritinib - Indolent Systemic Mastocytosis | Recruiting | Blueprint Medicines Corporation | 80 | 2025-12-09 | 2026-10-07 | |
| Peripheral Blood KIT-D816V Mutation in Adult Systemic Mastocytosis Systemic Mastocytosis, KIT-D816V Mutation | Recruiting | The First Affiliated Hospital of Soochow University | 50 | 2025-05-19 | 2026-05-01 | |
| Avapritinib Rollover Study Avapritinib - Mastocytosis, Systemic | Phase 4 | Recruiting | Blueprint Medicines Corporation | 60 | 2024-11-28 | 2026-02-09 |
| Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis No intervention - Mastocytosis, Systemic | Active not recruiting | Uppsala University | 400 | 2024-03-25 | 2025-04-04 | |
| Mastocytosis From Pediatric Age to Adulthood: Local Registry of Cutaneous and Systemic Mastocytosis Cutaneous Mastocytosis, Systemic Mastocytosis | Recruiting | Fondazione IRCCS Policlinico San Matteo di Pavia | 600 | 2024-01-26 | 2025-08-26 | |
| Angioedema Biomarker Research Study Venipuncture - Angioedema, Angioedemas, Hereditary | Recruiting | Foundation For Rare Disease Research | 600 | 2024-01-15 | 2026-08-24 | |
| Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies BLU-263, Azacitidine - Advanced Systemic Mastocytosis | Phase 1 | Terminated | Blueprint Medicines Corporation | 9 | 2023-09-25 | 2025-04-10 |
| A Registry for Patients With Systemic Mastocytosis in China Systemic Mastocytoses | Unknown | The First Affiliated Hospital of Soochow University | 150 | 2023-09-01 | 2023-10-10 | |
| Evaluation of the DALY on a Cohort of Patients With Indolent Systemic Mastocytosis Mastocytosis, Indolent Systemic | Unknown | University Hospital, Toulouse | 160 | 2023-05-01 | 2023-07-12 | |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies MGD024 - Leukemia, Acute Myeloid, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | MacroGenics | 130 | 2022-07-13 | 2026-07-28 |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets - SSM, Mastocytosis, Indolent | Phase 2 | Active not recruiting | Cogent Biosciences, Inc. | 237 | 2022-06-27 | 2026-10-22 |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis Elenestinib, Placebo - Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis | Phase 2 / Phase 3 | Recruiting | Blueprint Medicines Corporation | 534 | 2021-11-30 | 2026-10-07 |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis bezuclastinib - Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN) | Phase 2 | Recruiting | Cogent Biosciences, Inc. | 140 | 2021-11-09 | 2026-09-15 |
| Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis | Completed | Blueprint Medicines Corporation | 317 | 2020-12-02 | 2022-01-10 | |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis TL-895, Placebo - Myelofibrosis, Indolent Systemic Mastocytosis | Phase 2 | Unknown | Telios Pharma, Inc. | 121 | 2020-10-22 | 2024-05-10 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 |
Showing 20 of 97. Sign in to see all of them.
Leukemia, Mast-Cell (60) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (43) · Leukemia, Biphenotypic, Acute (42) · Leukemia, Hairy Cell (39) · Leukemia, Lymphocytic, Chronic, B-Cell (38) · Leukemia, Myeloid, Acute (38) · Leukemia, Large Granular Lymphocytic (36) · Leukemia, Myelomonocytic, Chronic (36) · Burkitt Lymphoma (35) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (33) · Leukemia, Prolymphocytic (33) · Lymphoma, Large-Cell, Anaplastic (33) · Mycosis Fungoides (33) · Sezary Syndrome (33)
Neoplasms by Histologic Type (97) · Immune System Diseases (95) · Mast Cell Activation Disorders (94) · Neoplasms (89) · Mastocytosis (80) · Hemic and Lymphatic Diseases (68) · Hematologic Diseases (66) · Leukemia, Myeloid (63) · Neoplasms, Connective and Soft Tissue (56) · Neoplasms, Connective Tissue (55) · Bone Marrow Diseases (49) · Pathological Conditions, Signs and Symptoms (49) · Immunoproliferative Disorders (48) · Lymphatic Diseases (48) · Disease Attributes (47)
Whole-Body Irradiation (6) · fludarabine phosphate (6) · Cyclosporine (5) · Mycophenolic Acid (5) · Therapeutics (5) · avapritinib (5) · Peripheral Blood Stem Cell Transplantation (4) · Psychiatric Rehabilitation (4) · midostaurin (4) · Imatinib Mesylate (3) · Acetaminophen (2) · Busulfan (2) · Cyclophosphamide (2) · Darbepoetin alfa (2) · Diphenhydramine (2)
Blueprint Medicines Corporation (10) · Fred Hutchinson Cancer Center (6) · M.D. Anderson Cancer Center (6) · Novartis Pharmaceuticals (5) · City of Hope Medical Center (4) · Mayo Clinic (4) · Wake Forest University Health Sciences (4) · Cogent Biosciences, Inc. (3) · Jason Robert Gotlib (3) · National Cancer Institute (NCI) (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · UNC Lineberger Comprehensive Cancer Center (3) · University Hospital, Toulouse (3) · AB Science (2) · Asan Medical Center (2)
United States (65) · France (17) · Germany (16) · Italy (15) · Netherlands (13) · Spain (13) · United Kingdom (13) · Canada (10) · Belgium (9) · Norway (9) · Australia (8) · Poland (8) · Austria (6) · Switzerland (6) · Denmark (4)
Srdan Verstovsek, MD (3) · David Maloney (2) · Elisabeth Paietta, PhD (2) · Jason Gotlib (2) · Jorge Cortes, MD (2) · Kyoo H. Lee, MD (2) · Luis Escribano, MD, PhD (2) · Rachael Easton, MD, PhD (2) · Adam J. Esbenshade, MD (1) · Ann Woolfrey (1) · Anthony F. Shields, MD, PhD (1) · Anthony L Boral, MD, PhD (1) · Aprille Seidel, PhD (1) · Barbara A. Murphy, MD (1)
PMID 35790816, PMID 27355533, PMID 32499241, PMID 35640224, PMID 15070706, PMID 16775235, PMID 17715389, PMID 18327587, PMID 18567837, PMID 18698002, PMID 19451433, PMID 20004787, PMID 21098399, PMID 21134978, PMID 21523798, PMID 22259028, PMID 22563089, PMID 23432617, PMID 23547655, PMID 24057647, PMID 24474568, PMID 26002753, PMID 26175532, PMID 26700120, PMID 26700123, PMID 28069279, PMID 28744009, PMID 29890238, PMID 30205939, PMID 31350306, PMID 32437738, PMID 32804590, PMID 33049057, PMID 34663404, PMID 34873345, PMID 34873347, PMID 35251038, PMID 35622074, PMID 36048877, PMID 38320129, PMID 39649724, PMID 40529483, PMID 41244098, PMID 41424055, PMID 41604606, PMID 41690487
P30CA015704 (5), P01CA018029 (3), 2016 (2), P30CA015083 (2), P30CA016086 (2), P30CA033572 (2), P30CA068485 (2), P30CA072720 (2), 2008 (1), 2015 (1), 2017 (1), 2018 (1), N01CM62202 (1), P01CA049605 (1), P01CA078902 (1)